We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.3B
AUM Growth
+$892M
Cap. Flow
+$30.9M
Cap. Flow %
0.25%
Top 10 Hldgs %
85.9%
Holding
130
New
9
Increased
23
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$33.7M
2
ASND icon
Ascendis Pharma A/S
ASND
+$17.1M
3
ONC
BeOne Medicines Ltd
ONC
+$16.8M
4
SAGE
Sage Therapeutics
SAGE
+$15.5M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$13.5M

Top Sells

Rank Stock Value
1
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$22.1M
2
AKAO
Achaogen Inc
AKAO
+$17.5M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$11.3M
4
BLUE
bluebird bio
BLUE
+$6.47M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 99.02%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANAB icon
76
AnaptysBio
ANAB
$1.71B
$3.89M 0.03%
111,386
-5,825
-5% -$157K
ADMS
77
DELISTED
Adamas Pharmaceuticals
ADMS
$3.65M 0.03%
172,630
– –
ARAV
78
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.52M 0.03%
239,536
-37,230
-13% -$3.76M
TNXP icon
79
Tonix Pharmaceuticals
TNXP
$215M
– –
0
– –
AKTX
80
Akari Therapeutics
AKTX
$15.3M
$3.05M 0.02%
621
– –
NTRA icon
81
Natera
NTRA
$47.9B
$2.95M 0.02%
228,676
– –
OVID icon
82
Ovid Therapeutics
OVID
$547M
$2.86M 0.02%
333,333
– –
MDGL icon
83
Madrigal Pharmaceuticals
MDGL
$11.9B
$2.6M 0.02%
57,762
– –
RARX
84
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$2.6M 0.02%
177,952
– –
TRVN
85
DELISTED
Trevena, Inc.
TRVN
$2.42M 0.02%
1,520
– –
KPTI icon
86
Karyopharm Therapeutics
KPTI
$44.5M
$2.38M 0.02%
14,466
– –
NVAX icon
87
Novavax
NVAX
$1.47B
$2.28M 0.02%
100,000
– –
ARGX icon
88
argenx
ARGX
$65B
$2.26M 0.02%
100,000
– –
TRIL
89
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.13M 0.02%
413,697
– –
KRYS icon
90
Krystal Biotech
KRYS
$10.3B
$1.99M 0.02%
+200,000
New +$2.02M
DVAX
91
DELISTED
Dynavax Technologies
DVAX
$1.61M 0.01%
75,000
– –
JNCE
92
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.56M 0.01%
100,000
– –
IMDZ
93
DELISTED
Immune Design Corp.
IMDZ
$1.54M 0.01%
148,937
– –
VIRX
94
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.44M 0.01%
21,190
– –
CLLS
95
Cellectis
CLLS
$342M
$1.42M 0.01%
50,000
– –
MDWD icon
96
MediWound
MDWD
$171M
$1.21M 0.01%
32,286
– –
ABUS icon
97
Arbutus Biopharma
ABUS
$1.03B
$1.12M 0.01%
180,582
– –
AIXC
98
AIxCrypto Holdings Inc
AIXC
$22.7M
$980K 0.01%
22
+19
+633% +$1.33M
AFMD
99
DELISTED
Affimed
AFMD
$900K 0.01%
40,000
– –
ADAP
100
DELISTED
Adaptimmune Therapeutics
ADAP
$819K 0.01%
100,000
– –
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2017 Portfolio in Review

As of Q3 2017, Julian Baker held 130 positions worth $12.3B, up 7.8% from $11.4B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2017 filing shows 9 new, 23 increased, 9 reduced and 9 closed positions. Its largest new stake was Acorda Therapeutics: 4,329 shares worth $12.3M. The largest sale was SANGAMO THERAPEUTICS INC, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q3 2017 buy was Acorda Therapeutics: 4,329 shares worth $12.3M.
  • Julian Baker added most to Array Biopharma Inc in Q3 2017, an estimated $33.7M increase.
  • Julian Baker's biggest Q3 2017 reduction was SANGAMO THERAPEUTICS INC, cutting an estimated $22.1M.
  • Julian Baker fully exited Zogenix, Inc. in Q3 2017, selling an estimated $2.69M.
  • Julian Baker's ten largest holdings make up 86% of its $12.3B portfolio in Q3 2017.
  • Julian Baker opened 9 new positions and closed 9 in Q3 2017.
  • Julian Baker's portfolio value rose 7.8% quarter-over-quarter to $12.3B.

Based on Baker Bros. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.